The 6 analysts offering 12-month price forecasts for EyePoint Pharmaceuticals Inc have a median target of 30.50, with a high estimate of 60.00 and a low estimate of 21.00. The median estimate represents a +285.59% increase from the last price of 7.91.
The current consensus among 6 polled investment analysts is to Buy stock in EyePoint Pharmaceuticals Inc. This rating has held steady since July, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.68
Reporting Date Nov 02
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.